RMD-008

RMD-008 is an investigational gene therapy candidate being developed by Remedium Technologies for the treatment of sarcopenia (age-related muscle loss). The therapy is built upon the company's proprietary Prometheus™ platform, which is designed to enable adjustable gene expression, allowing for precise control over the levels of the therapeutic protein produced. RMD-008 can be delivered using either adeno-associated virus (AAV) or lipid nanoparticle (LNP) vectors. As of early 2024, the program is in the in vivo proof-of-concept (POC) stage of development. While the specific molecular target or transgene has not been publicly disclosed, the therapy aims to address the functional decline and muscle wasting associated with sarcopenia.